167 related articles for article (PubMed ID: 26645899)
1. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
[TBL] [Abstract][Full Text] [Related]
2. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-4 receptor alpha overexpression in human bladder cancer correlates with the pathological grade and stage of the disease.
Joshi BH; Leland P; Lababidi S; Varrichio F; Puri RK
Cancer Med; 2014 Dec; 3(6):1615-28. PubMed ID: 25208941
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
5. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
[TBL] [Abstract][Full Text] [Related]
6. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
7. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
8. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
Puri RK
Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
Joshi BH; Kawakami K; Leland P; Puri RK
Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
Kornmann M; Kleeff J; Debinski W; Korc M
Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
[TBL] [Abstract][Full Text] [Related]
11. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
[TBL] [Abstract][Full Text] [Related]
12. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
13. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice.
Shapira S; Shapira A; Starr A; Kazanov D; Kraus S; Benhar I; Arber N
Gastroenterology; 2011 Mar; 140(3):935-46. PubMed ID: 21147107
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
15. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
16. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
17. Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy.
Kioi M; Takahashi S; Kawakami M; Kawakami K; Kreitman RJ; Puri RK
Cancer Res; 2005 Sep; 65(18):8388-96. PubMed ID: 16166317
[TBL] [Abstract][Full Text] [Related]
18. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
19. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
